SCNI · Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd. reported FY2025 revenue of $1.3 million, up 99% from $658 thousand in FY2024, driven by expansion of its CDMO platform intended to support a wider range of customer needs and increase client attraction and retention as described in Item 1 - Business. This growth reflects successful scaling of services post strategic initiatives, though it coincided with gross profit deteriorating to -$2.7 million from -$580 thousand, a -357% change, due to manufacturing costs outpacing topline in biologics and small-molecule production.

Operating income loss narrowed 12.7% to -$7.5 million from -$8.6 million, primarily from a decrease in allocation of employees and facilities to the R&D business unit, demonstrating capital efficiency focus. The company's R&D strategy, combining internally developed platform-based programs with externally sourced assets, prioritizes risk management and optionality, enabling cost discipline amid investments. This contributed to operating margin of -575%, highlighting leverage potential as revenue base grows.

Net income swung to a loss of -$8.3 million from a $4.8 million profit, a -273% change, attributable to the absence of prior-year non-operating gains such as debt restructuring benefits. Diluted EPS remained stable at $0.004, underscoring per-share consistency despite volatility.

Cash flow from operations used -$6.0 million, comparable to -$6.3 million prior year, with free cash flow at -$6.1 million after minimal $24 thousand capital expenditures. This low capex profile prioritizes cash preservation, aligning with management’s emphasis on efficiency in a capital-constrained biotech environment. Leadership expertise in capital markets, restructuring, and healthcare venture capital, as noted for key executives like Raviv and Margolin in Item 7, supports navigation of financing needs and treasury management.

Overall, results show revenue momentum from CDMO expansion balanced by gross margin pressure, with operating improvements signaling strategic pivots toward efficiency. Investors should note R&D grant liabilities from IIA funding, recognized when royalty-bearing sales are anticipated per Item 1A Risk Factors, as potential future offsets to ongoing losses.